Clinical Trials

Clinical trials are research studies to collect data, measure outcomes and assess the safety and effectiveness of a new drug or combination of drugs.

Deciphera is currently conducting a clinical trial on DCC-2036, a potent inhibitor of BCR-ABL kinase. DCC-2036 inhibits the drug resistant variants of BCR-ABL including the highly resistant T315I mutant form, which is resistant to all currently marketed therapies. DCC-2036 is currently being evaluated in leukemias caused by BCR-ABL kinase, including Philadelphia chromosome positive (Ph+)chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). DCC-2036 also potently inhibits FLT3-ITD, TRKA, and TIE2 kinases, which cause approximately 40% of acute myeloid leukemia (AML). Based on this profile, DCC-2036 is also being studied in refractory AML patients.

Additional information about this clinical trial is available at www.clinicaltrials.gov.